{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:45:52Z","timestamp":1782956752338,"version":"3.54.5"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["Grant for Young Investigators nr STM. C160.20.080."],"award-info":[{"award-number":["Grant for Young Investigators nr STM. C160.20.080."]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin II type 1 receptor (AT1R) antibodies are considered non-HLA (human leukocyte antigen) antibodies connected with humoral rejection after kidney transplantation. The role of AT1R antibodies in the pathogenesis of glomerular diseases and systemic vasculitis is unknown. We assessed the level of AT1R antibodies in 136 patients with different types of glomerulonephritis and systemic vasculitis and we observed kidney function and proteinuria, serum albumin and total protein levels for 2\u00a0years. The mean levels of AT1R antibodies were the following: 6.00\u2009\u00b1\u20091.31\u00a0U\/ml in patients with membranous nephropathy (<jats:italic>n<\/jats:italic>\u2009=\u200918), 5.67\u2009\u00b1\u20091.31\u00a0U\/ml with focal and segmental glomerulosclerosis (<jats:italic>n<\/jats:italic>\u2009=\u200925), 6.26\u2009\u00b1\u20092.25\u00a0U\/ml with lupus nephropathy (<jats:italic>n<\/jats:italic>\u2009=\u200917), 10.60\u2009\u00b1\u20096.72\u00a0U\/ml with IgA nephropathy (<jats:italic>n<\/jats:italic>\u2009=\u200914), 6.69\u2009\u00b1\u20092.52\u00a0U\/ml with mesangial proliferative (non IgA) glomerulonephritis (<jats:italic>n<\/jats:italic>\u2009=\u20096), 6.63\u2009\u00b1\u20091.38\u00a0U\/ml with systemic vasculitis (<jats:italic>n<\/jats:italic>\u2009=\u200956), including c-ANCA (anti-neutrophil cytoplasmic antibodies) vasculitis: 11.22\u2009\u00b1\u200910.78\u00a0U\/ml (<jats:italic>n<\/jats:italic>\u2009=\u200940) and p-ANCA vasculitis: 12.65\u2009\u00b1\u200914.59\u00a0U\/ml (<jats:italic>n<\/jats:italic>\u2009=\u200916). The mean AT1R antibodies level was higher in patients with lupus nephropathy and systemic vasculitis compared to glomerulonephritis groups. An inverse statistically significant correlation between AT1R antibodies and serum albumin (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.51) in membranous nephropathy group was also found. Prospective analysis of creatinine levels indicated an increase of creatinine levels during time among patients with higher AT1R antibodies levels in p-ANCA vasculitis. Lupus nephropathy and systemic vasculitis patients may have high levels of AT1R antibodies. AT1R antibodies may be associated with the severity of membranous nephropathy and the course of p-ANCA vasculitis, although influence of concomitant factors is difficult to exclude.<\/jats:p>","DOI":"10.1007\/s00005-022-00660-x","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T15:15:51Z","timestamp":1664032551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients"],"prefix":"10.2478","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1248-081X","authenticated-orcid":false,"given":"Maciej","family":"Szymczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Heidecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelina","family":"\u017babi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagna","family":"Rukasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wi\u015bnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Tukiendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Krajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Banasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"660_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12882-020-01910-w","volume":"21","author":"M Abuzeineh","year":"2020","unstructured":"Abuzeineh M, Aala A, Alasfar S et al (2020) Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria. BMC Nephrol 21:253","journal-title":"BMC Nephrol"},{"issue":"Suppl 1","key":"660_CR2","first-page":"153","volume":"18","author":"B Ajdinovic","year":"2015","unstructured":"Ajdinovic B, Dragovic T, Magic Z et al (2015) The importance of angiotensin II type 1 receptor gene polymorphism to losartan treatment in improving glomerulopathy in type 1 diabetic patients. Hell J Nucl Med 18(Suppl 1):153","journal-title":"Hell J Nucl Med"},{"key":"660_CR3","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41598-019-41536-z","volume":"9","author":"T Akaishi","year":"2019","unstructured":"Akaishi T, Abe M, Okuda H et al (2019) High glucose level and angiotensin II type 1 receptor stimulation synergistically amplify oxidative stress in renal mesangial cells. Sci Rep 9:5214","journal-title":"Sci Rep"},{"key":"660_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/tri.12371","volume":"27","author":"M Banasik","year":"2014","unstructured":"Banasik M, Boraty\u0144ska M, Ko\u015bcielska-Kasprzak K et al (2014a) The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int 27:1029\u20131038","journal-title":"Transpl Int"},{"key":"660_CR5","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.transproceed.2014.09.029","volume":"46","author":"M Banasik","year":"2014","unstructured":"Banasik M, Boraty\u0144ska M, Ko\u015bcielska-Kasprzak K et al (2014b) Non-HLA antibodies angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. Transplant Proc 46:2618\u20132621","journal-title":"Transplant Proc"},{"key":"660_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11\u201321","journal-title":"N Engl J Med"},{"key":"660_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/jpsu.2002.30266","volume":"37","author":"B Chertin","year":"2002","unstructured":"Chertin B, Rolle U, Cascio S et al (2002) Upregulation of angiotensin II receptors in reflux nephropathy. J Pediatr Surg 37:251\u2013255","journal-title":"J Pediatr Surg"},{"key":"660_CR8","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1681\/ASN.2019060597","volume":"30","author":"BSM Chow","year":"2019","unstructured":"Chow BSM, Kocan M, Shen M et al (2019) AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: Impact on the therapeutic targeting of renal and cardiac fibrosis. J Am Soc Nephrol 30:2191\u20132207","journal-title":"J Am Soc Nephrol"},{"key":"660_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ophtha.2008.12.021","volume":"116","author":"I Dimitrijevic","year":"2009","unstructured":"Dimitrijevic I, Malmsj\u00f6 M, Andersson C et al (2009) Increased angiotensin II type 1 receptor expression in temporal arteries from patients with giant cell arteritis. Ophthalmology 116:990\u2013996","journal-title":"Ophthalmology"},{"key":"660_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3109\/03009742.2011.593545","volume":"40","author":"I Dimitrijevic","year":"2011","unstructured":"Dimitrijevic I, Rissler P, Luts L et al (2011) Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener\u2019s granulomatosis). Scand J Rheumatol 40:448\u2013452","journal-title":"Scand J Rheumatol"},{"key":"660_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","volume":"352","author":"D Dragun","year":"2005","unstructured":"Dragun D, M\u00fcller DN, Br\u00e4sen JH et al (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352:558\u2013569","journal-title":"N Engl J Med"},{"key":"660_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41598-020-80209-0","volume":"11","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, Ichikawa D, Sugaya T et al (2021) Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion. Sci Rep 11:982","journal-title":"Sci Rep"},{"key":"660_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000346954","volume":"122","author":"W Hayashi","year":"2012","unstructured":"Hayashi W, Obata Y, Nishino T et al (2012) Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. Nephron Exp Nephrol 122:13\u201322","journal-title":"Nephron Exp Nephrol"},{"key":"660_CR14","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1681\/ASN.2019010053","volume":"30","author":"K Inoue","year":"2019","unstructured":"Inoue K, Tian X, Velazquez H et al (2019) Inhibition of endocytosis of clathrin mediated angiotensin II receptor Type 1 in podocytes augments glomerular injury. J Am Soc Nephrol 30:2307\u20132320","journal-title":"J Am Soc Nephrol"},{"key":"660_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.trsl.2011.05.003","volume":"158","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Kondo S, Urushihara M et al (2011) Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis. Transl Res 158:235\u2013248","journal-title":"Transl Res"},{"key":"660_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.126.4.607","volume":"126","author":"D Koffler","year":"1967","unstructured":"Koffler D, Schur PH, Kunkel HG (1967) Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 126:607\u2013624","journal-title":"J Exp Med"},{"key":"660_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.5414\/CNP72457","volume":"72","author":"YT Lee","year":"2009","unstructured":"Lee YT, Chiu HC, Huang CT et al (2009) The A1166C polymorphism of angiotensin II Type 1 receptor as a predictor of renal function decline over 4 years follow-up in an apparently healthy Chinese population. Clin Nephrol 72:457\u2013467","journal-title":"Clin Nephrol"},{"key":"660_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2019.01.030","volume":"96","author":"C Lefaucher","year":"2019","unstructured":"Lefaucher C, Viglietti D, Bouatou Y et al (2019) Non-HLA agonistic anti-angiotensin II type receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int 96:189\u2013201","journal-title":"Kidney Int"},{"key":"660_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.kint.2020.07.047","volume":"99","author":"DE Leisman","year":"2021","unstructured":"Leisman DE, Fernandes TD, Bijol V et al (2021) Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury. Kidney Int 99:148\u2013160","journal-title":"Kidney Int"},{"key":"660_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0961203320904787","volume":"29","author":"JM Mejia-Vilet","year":"2020","unstructured":"Mejia-Vilet JM, Lopez-Hernandez YJ, Santander-Velez JI et al (2020) Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis. Lupus 29:371\u2013378","journal-title":"Lupus"},{"key":"660_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","volume":"71","author":"Z Moldoveanu","year":"2007","unstructured":"Moldoveanu Z, Wyatt RJ, Lee JY et al (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148\u20131154","journal-title":"Kidney Int"},{"key":"660_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ajh\/hpaa071","volume":"33","author":"MC Philogene","year":"2020","unstructured":"Philogene MC, Han D, Alvarado F et al (2020) Prevalence of angiotensin II Type 1 receptor antibodies in persons with hypernsion and relation to blood pressure and medication. Am J Hypertens 33:734\u2013740","journal-title":"Am J Hypertens"},{"key":"660_CR23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/jch.13351","volume":"20","author":"C Sabbadin","year":"2018","unstructured":"Sabbadin C, Ceccato F, Ragazzi E et al (2018) Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens 20:1313\u20131318","journal-title":"J Clin Hypertens"},{"key":"660_CR24","doi-asserted-by":"publisher","first-page":"F644","DOI":"10.1152\/ajprenal.00550.2020","volume":"320","author":"J Schrankl","year":"2021","unstructured":"Schrankl J, Fuchs M, Broeker K et al (2021) Localization of angiotensin II Type 1 receptor gene expression in rodent and human kidneys. Am J Physiol Renal Physiol 320:F644\u2013F653","journal-title":"Am J Physiol Renal Physiol"},{"key":"660_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(74)90377-8","volume":"1","author":"EJ Shillitoe","year":"1974","unstructured":"Shillitoe EJ, Lehner T, Lessof MH et al (1974) Letter: Immunological features of Wegener\u2019s granulomatosis. Lancet 1:929","journal-title":"Lancet"},{"key":"660_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2020.100573","volume":"34","author":"BM Sorohan","year":"2020","unstructured":"Sorohan BM, Ismail G, Leca N et al (2020) Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review. Transplant Rev 34:100573","journal-title":"Transplant Rev"},{"key":"660_CR27","doi-asserted-by":"publisher","first-page":"F267","DOI":"10.1152\/ajprenal.00059.2003","volume":"286","author":"H Suzuki","year":"2004","unstructured":"Suzuki H, Yamamoto T, Ikegaya N et al (2004) Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am J Physiol Renal Physiol 286:F267-277","journal-title":"Am J Physiol Renal Physiol"},{"key":"660_CR28","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2353\/ajpath.2007.060484","volume":"170","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Han GD, Miyauchi N et al (2007) Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 170:1841\u20131853","journal-title":"Am J Pathol"},{"key":"660_CR29","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/ajt.12395","volume":"13","author":"M Taniguchi","year":"2012","unstructured":"Taniguchi M, Rebellato LM, Cai J et al (2012) Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 13:2577\u20132589","journal-title":"Am J Transplant"},{"key":"660_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajpath.2019.02.004","volume":"189","author":"Y Wen","year":"2019","unstructured":"Wen Y, Rudemiller NP, Zhang J et al (2019) Stimulating Type 1 angiotensin receptors on T lymphocytes attenuates renal fibrosis. Am J Pathol 189:981\u2013988","journal-title":"Am J Pathol"},{"key":"660_CR31","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/ijcp.12242","volume":"67","author":"J Xiong","year":"2013","unstructured":"Xiong J, Liang Y, Yang H et al (2013) The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract 67:1066\u20131067","journal-title":"Int J Clin Pract"},{"key":"660_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3343\/alm.2020.40.5.398","volume":"40","author":"S Yu","year":"2020","unstructured":"Yu S, Huh HJ, Lee KW et al (2020) Pre-transplant angiotensin II Type 1 receptor antibodies and anti-endothelial cell antibodies predict graft function and allograft rejection in a low-risk kidney transplantation setting. Ann Lab Med 40:398\u2013408","journal-title":"Ann Lab Med"},{"key":"660_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nm.1856","volume":"14","author":"CC Zhou","year":"2008","unstructured":"Zhou CC, Zhang Y, Irani RA et al (2008) Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 14:855\u2013862","journal-title":"Nat Med"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-022-00660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00005-022-00660-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-022-00660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:49:53Z","timestamp":1704228593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00005-022-00660-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s00005-022-00660-x","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations."}},{"value":"All authors declare no conflict of interest. Blood analysis was performed by CELLTREND (Luckenwalde, Germany) free of charge. Maciej Szymczak, Marcelina \u017babi\u0144ska, Dagna Rukasz, Krzysztof Grubizna, Magdalena Krajewska, Miros\u0142aw Banasik have nothing to disclose. Harald Heidecke is CEO and stakeholder of Celltrend GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"23"}}